Touchstone Health Announces Appointment of Michael A. Muchnicki as President & Chief Executi... ( NEW YORK Feb. 5 /- Touchstone Hea...)

Touchstone Health Announces Appointment of Michael A. Muchnicki as President & Chief Executive Officer

Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire/ -- Touchstone Health HMO, Inc. announced today that Michael A. Muchnicki has recently joined the organization as President & Chief Executive Officer.

"We are extremely pleased to have Michael join Touchstone Health," says Steven Wiggins, Investor and Board Member of Touchstone Health. "His significant experience and expertise in leading organizations to success will further our growth and help us establish Touchstone Health as a leader in the New York marketplace."

"I am excited to be at Touchstone Health to further the growth and development of the company," says Muchnicki. "Touchstone Health has a rich New York history and I look forward to working with our government partners to provide great service to our members."

Muchnicki, an experienced Senior Executive in the Health Insurance industry, served as President of Vista Healthplans, Inc. in Florida, which was acquired by Coventry Health Care, Inc. in 2007. He spent most of his career at UnitedHealth Group as President and CEO of the Ohio, Louisiana and South Florida markets. In addition, he served as a Regional Vice President for the Southeast and Caribbean markets for CIGNA HealthCare. Muchnicki brings more than 20 years of managed care experience to Touchstone Health.

About Touchstone Health

Touchstone Health, headquartered in New York City, is an HMO focused on the Medicare market. Touchstone Health currently has 9,000 Medicare beneficiaries in the Bronx, Kings, Queens, Richmond, Orange, Westchester, Broome, Chenango, Delaware & Onondaga counties. Benefits are available to anyone enrolled in both Medicare Part A and B and continue to pay their Medicare applicable premiums.

Touchstone Health is a privately held company owned and advised by, among other investors, Lehman Brothers Venture Capital, Essex Woodlands Health Ventures and Steven Wiggins. The company was originally formed to manage the medical services of enrollees of other
'/>"/>

SOURCE Touchstone Health HMO, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science

Post Your Comments:

(Date:11/27/2009)...ov.27/PRNewswire-FirstCall/--TheGymboreeCorporatio...willpresentattheNASDAQOMX23rdInvestorProgram,which...esday,December2,2009,at11:45a.m.GMT. ,, Toliste...ationovertheInternet,pleaselogontowww.gymboree.com...storandMediaRelations"andthen"ConferenceCalls&...

(Date:11/27/2009)...INE,France,Nov.27/PRNewswire/--TeamGarmin-Slipstre...dtoethicalsportinganddevelopingthenextgenerationof...mGarmin-TransitionswiththeadditionofTransitionsOpt...world,sleadingmanufacturerofadaptiveeyewear,offeri...selectionofspectaclelensessuchasTransitionslensesa...

(Date:11/27/2009)... XenaCare Holdings has announced that it has be...n, one of the largest nonprofit organizations dedi...ation. , Delray Beach, FL...nc. (OTCBB: XCHO), a company specializing in the m...hcare products, has announced today that is has be...

(Date:11/27/2009)... unprecedented medical, economic burdens, study pr...ws) -- The number of people with diabetes in the U...5 years, a new study predicts. , That would bri...with the disease, up from 23.7 million today. , ,...th diabetes will triple, the study also warns, ris...

(Date:11/27/2009)... Voyant Health™ announced today that Spec...its TraumaCad Enterprise orthopedic templating sol... , (PRWEB) November 27, 20...ectrum Health (Grand Rapids, Michigan) has license...olution and its TraumaCad Extend workflow solution...

Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4 Health News:Diabetes Cases Expected to Double in 25 Years 2 Health News:Diabetes Cases Expected to Double in 25 Years 3 Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2 Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3

[0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program [0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor [0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation [0] Diabetes Cases Expected to Double in 25 Years [0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend

..., May 7 Conseco, Inc. (NYSE: CNO ),today reporte...t a new quarterly sales record with an increase of...ieur said. "This performance included,an 11% incre...surance Group,s sales declined 21%, but specified ...

...is common in the aggressive form of the disease, r...althDay News) -- For the first time, a gene linked... has been identified, researchers report. , "This ...ldhood Cancer Research at The Children,s Hospital ...

...ON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), ...esented today at a major scientific meeting findin...NIV, a selective alpha-2A-agonist. This compound,...(ADHD)., The data demonstrated that INTUNIV showed...

...ct Examination Finds Serious Violations in Long-Te... Acting Insurance,Commissioner Joel Ario today ann...ich was necessary due to a pattern of consumer har...2.3 million fine and an additional $30,million in ...

....3 million fine, CARMEL, Ind., May 7 Conseco, In...g state insurance regulators and two of,its insura...(CSHI) Company,and Bankers Life and Casualty Compa...e claims practices and,procedures, complaint handl...

...y 7 Longer life expectancy, greater,interest in s...ccess are,all factors fueling growth in sales of o...ted $68.4 billion in 2007 sales, with a 3.9% CAGR ... BTC and Other Growth Trends, this market should e...

Conseco Reports First Quarter Results Gene Variation Linked to Neuroblastoma, a Childhood Cancer Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms Insurance Department Fines Conseco Under Pennsylvania-Led, Multi-State Agreement Conseco Reaches Settlement of Multistate Market Conduct Examination Self-Medication One of Many Factors Driving OTC Drug Market Past $80 Billion by 2012

(Date:11/26/2009)...hAfrica,Nov.26/PRNewswire/--The2009Frost&Sulli...rmaceuticalMarketispresentedtoCiplaMedproSouthAfri...-bin/prnh/20081117/FSLOGO ) ,, FortheCompanyoft...kCiplaMedpro,sperformanceagainstkeycompetitors:gro...usinessprocesses,productsand/ortechnologiesandlead...

(Date:11/25/2009)....25/PRNewswire-FirstCall/--AmericanScientificResou...announcethattheyhaveopenedaregionalmarketingandpro...hasbeenabletosecurealocationabroad,providinganesse...tandfuturehealthandsafetyproductsforchildrenandadu...anyhousesinventoryinthestateofOhiowheretheywillals...

(Date:11/25/2009)....25/PRNewswire-FirstCall/--Hologic,Inc.(Hologicort...cturerandsupplierofpremiumdiagnostics,medicalimagi...ealthcareneedsofwomen,isusingtheannualmeetingofthe...PlaceinChicago,November29throughDecember3,2009tohi...osticmammographyworkstationsoftware. ,, TheHolo...

[0] Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market [0] American Scientific Resources Inc. Opens Shanghai Location [0] New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity

...of patients with multiple sclerosis, remained re...l FTY720,- New data demonstrate 89% of patients fr...used by MS - three years after starting treatment,...disability, affects 2.5 million people wo...latory filings planned before end of 2009 in US an...

...tes potential for once daily oral d...neration MEK inhibitor, RDEA436, to enter Phase 1 ...2008 -, SAN DIEGO, April 15 Ardea Biosciences, I... presented demonstrating the,potent activity and f...mitogen-activated ERK kinase (MEK) inhibitor famil...

Other Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 2 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 3 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 4

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

...ic protein produced and stored in somatotrophs in ...the pituitary into the bloodstream in a pulsatile ...c somatostatin (SS) and GH-releasing factor (GHRF)...rs to be regulated by somatostatin, while the ampl...

...ocorticoid produced by the human adrenal cortex. I...y to corticosteroid-binding globulin (CBG), with t...ts on specific intracellular receptors with effect...e function, glucose counter-regulation, vascular t...

...F-I or somatomedin C) is a 7.6 kDa peptide produce...gen of cellular proliferation, exerting its action...n the circulation, IGF-I is bound to IGF-binding p...ions of IGF-I by modulating the interaction of IGF...

Medicine Products:

Bioactive hGH ELISA Test Cortisol RIA Test IGF-I IRMA Test (With Extraction)IGF-I IRMA Test (Non-Extraction)

Touchstone Health Announces Appointment of Michael A. Muchnicki as President & Chief Executi...( NEW YORK Feb. 5 /- Touchstone Hea...),Health